E. Duroyon

发表

Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients

M. Fontenay, O. Hermine, V. Asnafi, 2022, Blood Cancer Journal.

Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients *

F. Carrat, P. Fenaux, T. Cluzeau, 2021, The British journal of dermatology.

VEXAS syndrome is characterized by blood and tissues inflammasome pathway activation and monocyte dysregulation

P. Raynaud, F. Carbone, D. Duffy, 2022, medRxiv.

PCR‐Fluo‐ASXL1‐FA: A fast, sensitive and inexpensive complementary method to detect ASXL1 mutations in haematological malignancies

O. Kosmider, M. Coudé, L. Darnige, 2022, International journal of laboratory hematology.

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

P. Tassone, P. Tagliaferri, A. Giordano, 2021, Journal for ImmunoTherapy of Cancer.

Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

C. E. Pedreira, J. Miguel, M. Schilham, 2020, Modern Pathology.

Pleuropulmonary manifestations of VEXAS syndrome.

R. Borie, E. Lazaro, M. Debray, 2022, Chest.

Atypical splice site mutations causing VEXAS syndrome.

J. Rossignol, O. Hermine, O. Kosmider, 2021, Rheumatology.

VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation

D. Duffy, O. Kosmider, Marine Luka, 2024, Nature communications.